Vabysmo FDA Approval History
Last updated by Judith Stewart, BPharm on Oct 30, 2023.
FDA Approved: Yes (First approved January 28, 2022)
Brand name: Vabysmo
Generic name: faricimab-svoa
Dosage form: Intravitreal Injection
Company: Genentech, Inc.
Treatment for: Macular Degeneration, Diabetic Macular Edema, Macular Edema
Vabysmo (faricimab-svoa) is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).
- Wet age-related macular degeneration is caused by growth of abnormal blood vessels into the macula. Diabetic macular edema occurs when damaged blood vessels in the retina leak into and cause swelling in the macula. Retinal vein occlusion occurs when there is a blockage in the retinal vein, which leads to retinal swelling (macular edema).
- Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) both contribute to vision loss by destabilizing blood vessels, causing inflammation and the formation of new leaky blood vessels. Vabysmo works to stabilize blood vessels by blocking pathways involving Ang-2 and VEGF-A.
- Vabysmo is administered by intravitreal injection.
- Warnings and precautions associated with Vabysmo include endophthalmitis and retinal detachments, increases in intraocular pressure, and potential risk of arterial thromboembolic events.
- Common adverse reactions include cataract and conjunctival hemorrhage.
Development timeline for Vabysmo
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
